Immunic, Inc. (IMUX)
7.96
-0.68
(-7.87%)
USD |
NASDAQ |
Oct 02, 16:00
7.95
-0.01
(-0.13%)
After-Hours: 20:00
Immunic Net Income (Quarterly) : -34.10M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -34.10M |
| March 31, 2026 | -32.59M |
| December 31, 2025 | -19.30M |
| September 30, 2025 | -25.58M |
| June 30, 2025 | -26.82M |
| March 31, 2025 | -25.47M |
| December 31, 2024 | -25.18M |
| September 30, 2024 | -24.37M |
| June 30, 2024 | -21.38M |
| March 31, 2024 | -29.58M |
| December 31, 2023 | -21.57M |
| September 30, 2023 | -22.77M |
| June 30, 2023 | -24.00M |
| March 31, 2023 | -25.27M |
| December 31, 2022 | -56.47M |
| September 30, 2022 | -21.22M |
| June 30, 2022 | -21.90M |
| March 31, 2022 | -20.81M |
| December 31, 2021 | -21.18M |
| September 30, 2021 | -19.29M |
| June 30, 2021 | -17.93M |
| March 31, 2021 | -34.53M |
| December 31, 2020 | -11.16M |
| September 30, 2020 | -12.91M |
| June 30, 2020 | -11.46M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.487M |
| December 31, 2019 | -7.691M |
| September 30, 2019 | -8.215M |
| June 30, 2019 | -14.71M |
| March 31, 2019 | -4.313M |
| December 31, 2018 | -4.812M |
| September 30, 2018 | -1.797M |
| June 30, 2018 | -2.67M |
| March 31, 2018 | -14.39M |
| December 31, 2017 | -14.59M |
| September 30, 2017 | -12.48M |
| June 30, 2017 | -12.41M |
| March 31, 2017 | -12.60M |
| December 31, 2016 | -11.73M |
| September 30, 2016 | -10.18M |
| June 30, 2016 | -9.468M |
| March 31, 2016 | -9.589M |
| December 31, 2015 | -9.859M |
| September 30, 2015 | -12.30M |
| June 30, 2015 | -15.11M |
| March 31, 2015 | -14.76M |
| December 31, 2014 | -13.96M |
| September 30, 2014 | -12.80M |
| June 30, 2014 | -10.17M |
| March 31, 2014 | -10.75M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Sionna Therapeutics, Inc. | -29.89M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 34.10M |
| EPS Diluted (Quarterly) | -0.8021 |
| Enterprise Value | -45.92M |
| Earnings Yield | -60.38% |
| Normalized Earnings Yield | -60.37 |